康莱特注射液联合化疗治疗非小细胞肺癌62例临床观察  

Combination of Kanglaite Injection and PTX+CBP Chemotherapy in the Treatment of Non-small-cell Lung Cancer

作　　者：姜福胜[1] 魏博[1] 张广亮[1] 杨国榜[1] 李维青[1] 

机构地区：[1]北京世纪坛医院胸外科,北京100038

出　　处：《临床医药实践》2010年第3X期345-347,共3页Proceeding of Clinical Medicine

摘　　要：目的:观察康莱特注射液与化疗联用对非小细胞肺癌(NSCLC)的治疗效果。方法:将62例中晚期NSCLC患者随机分为康莱特联合紫杉醇+卡铂(PTX+CBP)(PC方案)组和单纯PC方案化疗组。结果:两组有效率分别为53.1%和36.6%,差异有统计学意义(P<0.05),联合组治疗前后KPS评分改善及稳定者明显高于单纯化疗组(P<0.05)。结论:应用康莱特能使患者KPS提高或保持稳定,有助于提高化疗疗效。Objective:The aim of the trial was to evaluate the curative effect of Kanglaite(KLT) on non-small-cell lung cancer.Methods:Sixty-two patients with non-small-cell lung cancer were divided into the KLT-Paclitaxel(PTX) )/ Carboplatin(CBP) combination treatment group of 32 cases and the chemotherapy group alone of 30 cases.Results:The results showed that the effective rate in combination treatment group was 53.1%,which was significantly higher than 36.6% of the control group(P<0.05);the change of general condition(KPS) after treatment had marked difference(P<0.05).Conclusion:This study suggest that KLT used in combination with PC in the tretment of NSCLC would improve therapeutic effects and KPS.

关 键 词：非小细胞肺癌 薏苡仁 紫杉醇 卡铂 联合化疗 

分 类 号：R734.2[医药卫生—肿瘤]